date,title,source
Nov-01-18,AzurRx BioPharma Receives Sanction of Cystic Fibrosis Therapeutics Development Network for the Study of MS1819-SD in CF Patients with EPI,GlobeNewswire
Dec-04-18,AZRX: 3Q:18 Financial and Operational Summary,Zacks Small Cap Research
Dec-04-18,AzurRx BioPharma to Present at Upcoming Investor Conferences,GlobeNewswire
Dec-12-18,AzurRx BioPharma to Acquire Payment Rights to Lead Drug Candidate MS1819-SD from Protea Biosciences Group,GlobeNewswire
Dec-19-18,AzurRx BioPharma Announces Initiation of Phase II OPTION Clinical Trial of MS1819-SD in Cystic Fibrosis Patients,GlobeNewswire
Feb-20-19,AzurRx BioPharma Announces First Patients Dosed in Phase II OPTION Clinical Trial,GlobeNewswire
Mar-12-19,AzurRx BioPharma Announces Poster Presentation at the Americas Hepato-Pancreato-Biliary Association 2019 Annual Meeting,GlobeNewswire
